Spectrum Pharmaceuticals Inc. (SPPI)

17.11
0.59 3.50
NASDAQ : Health Technology
Prev Close 16.52
Open 17.07
Day Low/High 16.60 / 18.15
52 Wk Low/High 9.55 / 25.29
Volume 3.98M
Avg Volume 1.43M
Exchange NASDAQ
Shares Outstanding 104.06M
Market Cap 2.22B
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Spectrum Pharmaceuticals Announces Release Of Updated Poziotinib Data From MD Anderson Phase 2 Study In Non-Small Cell Lung Cancer Patients

Spectrum Pharmaceuticals Announces Release Of Updated Poziotinib Data From MD Anderson Phase 2 Study In Non-Small Cell Lung Cancer Patients

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced preliminary poziotinib data from the University of...

Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy And Doses First Patient

Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy And Doses First Patient

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has initiated two new cohorts for...

Spectrum Pharmaceuticals Announces Release Of Poziotinib Abstract As Part Of The IASLC 19th World Conference On Lung Cancer

Spectrum Pharmaceuticals Announces Release Of Poziotinib Abstract As Part Of The IASLC 19th World Conference On Lung Cancer

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced new interim poziotinib data from the MD Anderson...

Spectrum Pharmaceuticals To Present At Two Upcoming Investor Conferences In September

Spectrum Pharmaceuticals To Present At Two Upcoming Investor Conferences In September

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGN, DSS, ENDP, ICUI, PIH, SPB, SPPI, WAAS, YRD Downgrades: BMA, BRT, ELSE, FRBK, HAE, HSKA, JD, MATW, TCMD, TSG Initiations: ALT, TRTX Read on to get TheStreet Quant Ratings' detailed report:

Spectrum Pharmaceuticals Reports Second Quarter 2018 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports Second Quarter 2018 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period ended...

Spectrum Pharmaceuticals Announces Second Quarter 2018 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Second Quarter 2018 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management...

Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data At MASCC 2018 And Announces The Phase 3 RECOVER Study Met The Primary Endpoint

Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data At MASCC 2018 And Announces The Phase 3 RECOVER Study Met The Primary Endpoint

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced detailed data from the ADVANCE Phase 3 study which...

Spectrum Pharmaceuticals To Host Conference Call Highlighting ROLONTIS® (eflapegrastim) Phase 3 ADVANCE Study Data Presented At Multinational Association Of Supportive Care in Cancer (MASCC)

Spectrum Pharmaceuticals To Host Conference Call Highlighting ROLONTIS® (eflapegrastim) Phase 3 ADVANCE Study Data Presented At Multinational Association Of Supportive Care in Cancer (MASCC)

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the company will hold a conference call on Friday, June 29...

CORRECTING And REPLACING Spectrum Pharmaceuticals Announces Detailed Results From Phase 3 Study Of ROLONTIS® (eflapegrastim) Published In An ASCO Abstract

CORRECTING And REPLACING Spectrum Pharmaceuticals Announces Detailed Results From Phase 3 Study Of ROLONTIS® (eflapegrastim) Published In An ASCO Abstract

Fourth paragraph, first sentence of release dated May 16, 2018, should read: "The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes one Phase 2 and two Phase 3 clinical studies involving approximately 800 patients" (instead...

Spectrum Pharmaceuticals To Present Corporate Update At The Bank Of America Merrill Lynch 2018 Health Care Conference On May 16th

Spectrum Pharmaceuticals To Present Corporate Update At The Bank Of America Merrill Lynch 2018 Health Care Conference On May 16th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and...

Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period ended...

Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement On Certain Methods Of Use Of Poziotinib With The University Of Texas MD Anderson Cancer Center

Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement On Certain Methods Of Use Of Poziotinib With The University Of Texas MD Anderson Cancer Center

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today an exclusive licensing agreement with The University...

Spectrum Pharmaceuticals Enters Into A Next-Generation Sequencing Companion Diagnostic Partnership With Thermo Fisher Scientific

Spectrum Pharmaceuticals Enters Into A Next-Generation Sequencing Companion Diagnostic Partnership With Thermo Fisher Scientific

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it has entered into an agreement with Thermo Fisher...

Spectrum Pharmaceuticals Announces Corporate Governance Enhancements And Board Changes

Spectrum Pharmaceuticals Announces Corporate Governance Enhancements And Board Changes

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today that it has taken a number of actions designed to...

Company Profile For SPECTRUM PHARMACEUTICALS

Company Profile For SPECTRUM PHARMACEUTICALS

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.

Spectrum Pharmaceuticals Announces First Quarter 2018 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces First Quarter 2018 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management...

Spectrum Pharmaceuticals Announces Publication Of Poziotinib Data In Nature Medicine

Spectrum Pharmaceuticals Announces Publication Of Poziotinib Data In Nature Medicine

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced a publication entitled, "Mechanisms and clinical...

Spectrum Pharmaceuticals To Present Corporate Update At The H.C. Wainwright Global Life Sciences Conference On April 10th

Spectrum Pharmaceuticals To Present Corporate Update At The H.C. Wainwright Global Life Sciences Conference On April 10th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACSF, ATRC, BKE, CRSP, HALO Downgrades: GIFI, GTE, MGI, NNI, RBBN, SHAK, SPPI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Spectrum Pharmaceuticals To Present Corporate Update At The Cowen And Company 38th Annual Health Care Conference On March 13th

Spectrum Pharmaceuticals To Present Corporate Update At The Cowen And Company 38th Annual Health Care Conference On March 13th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Spectrum Pharmaceuticals Reports Fourth Quarter 2017 And Full Year 2017 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports Fourth Quarter 2017 And Full Year 2017 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today financial results...

Spectrum Pharmaceuticals Announces Appointment Of William L. Ashton To Its Board Of Directors

Spectrum Pharmaceuticals Announces Appointment Of William L. Ashton To Its Board Of Directors

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced the appointment of...

Spectrum Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a...

Spectrum Pharmaceuticals To Present Corporate Update At The 2018 RBC Capital Markets Global Healthcare Conference On February 22nd

Spectrum Pharmaceuticals To Present Corporate Update At The 2018 RBC Capital Markets Global Healthcare Conference On February 22nd

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Spectrum Pharmaceuticals Announces ROLONTIS™ (eflapegrastim) Met The Primary Endpoint In The Phase 3 ADVANCE Study

Spectrum Pharmaceuticals Announces ROLONTIS™ (eflapegrastim) Met The Primary Endpoint In The Phase 3 ADVANCE Study

Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the first Phase...

First Week of March 16th Options Trading For Spectrum Pharmaceuticals (SPPI)

First Week of March 16th Options Trading For Spectrum Pharmaceuticals (SPPI)

Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the March 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new March 16th contracts and identified one put and one call contract of particular interest.

TheStreet Quant Rating: C (Hold)